

company announcement

Novo Nordisk A/S – Share repurchase programme

Bagsværd, Denmark, 20 April 2020 – On 5 February 2020, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 17 billion to be executed during a 12-month period beginning 5 February 2020.

Under the programme, initiated 5 February 2020, Novo Nordisk will repurchase B shares for an amount up to DKK 2.9 billion in the period from 5 February 2020 to 4 May 2020.

Since the announcement as of 6 April 2020, the following transactions have been made:

	Number of B shares	Average purchase price	Transaction value, DKK
Accumulated, last announcement	5,090,000		2,051,311,073
6 April 2020	115,000	416.71	47,922,158
7 April 2020	115,000	412.14	47,395,663
8 April 2020	115,000	403.30	46,379,800
14 April 2020	115,000	404.37	46,503,071
15 April 2020	115,000	413.28	47,527,761
16 April 2020	115,000	417.62	48,026,349
17 April 2020	115,000	426.67	49,067,218
Accumulated under the programme	5,895,000		2,384,133,093

The details for each transaction made under the share repurchase programme are published on novonordisk.com.

With the transactions stated above, Novo Nordisk owns a total of 55,923,609 B shares of DKK 0.20, corresponding to 2.3% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,400,000,000 including treasury shares.

Novo Nordisk expects to repurchase B shares for an amount up to DKK 17 billion during a 12-month period beginning 5 February 2020. As of 17 April 2020, Novo Nordisk has since 5 February 2020 repurchased a total of 5,895,000 B shares at an average share price of DKK 404.43 per B share equal to a transaction value of DKK 2,384,133,093.

Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,700 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, [Facebook](#), [Twitter](#), [LinkedIn](#), [YouTube](#).

Further information

Media:

Anne Margrethe Hauge	+45 4442 3450	amhg@novonordisk.com
Ken Inchausti (US)	+1 609 240 9429	kiau@novonordisk.com

Investors:

Daniel Muusmann Bohsen	+45 3075 2175	dabo@novonordisk.com
Valdemar Borum Svarrer	+45 3079 0301	jvls@novonordisk.com
Ann Søndermølle Rendbæk	+45 3075 2253	arnd@novonordisk.com
Mark Joseph Root	+45 3079 4211	mjhr@novonordisk.com
Kristoffer Due Berg (US)	+1 609 235 2989	krdb@novonordisk.com